Association of Saquinavir Plasma Concentrations with Side Effects but Not with Antiretroviral Outcome in Patients Infected with Protease Inhibitor-Susceptible Human Immunodeficiency Virus Type 1
Open Access
- 1 September 2007
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (9) , 3264-3272
- https://doi.org/10.1128/aac.00036-07
Abstract
The objective of this study was to identify parameters among saquinavir pharmacokinetics, patients' demographics or comedications, to be addressed for improved personalized therapy. The presence of human immunodeficiency virus type 1 (HIV-1) RNA at therapy week 48 (principal target parameter), CD4 cell count at week 48, infections and side effects during 48 weeks, indicators of liver toxicity and lipid abnormalities at week 48, and a 12-h saquinavir plasma concentration-versus-time profile were assessed in 56 patients receiving saquinavir-ritonavir (1,000 and 100 mg, respectively) twice daily (44 therapy-naïve and 12 antiretrovirally pretreated patients) for association with saquinavir plasma concentrations, demographics, baseline values of target parameters, and coadministered antiretrovirals. Antiretroviral failure was observed in 8 of the 56 patients in whom HIV-1 RNA was detectable at week 48. This therapeutic failure was not associated with individual saquinavir pharmacokinetics. More likely, therapeutic failure was related to incidences interfering with antiretroviral therapy, causing therapy interruptions or incompliance. Weak associations were, however, seen between high maximum saquinavir plasma concentrations and both CD4 counts of ≥200 cells μl−1at week 48 (P= 0.014) and constitutional side effects during 48 weeks (P= 0.002). However, patients with high CD4 counts and constitutional side effects were not identical (P= 0.53). Saquinavir therapeutic drug monitoring in patients infected with protease inhibitor-susceptible HIV-1 taking saquinavir-ritonavir (1,000 and 100 mg, respectively) is not demanded for improving the antiretroviral effect. It may be contemplated in cases with constitutional side effects or low CD4 counts with weak immune responses.This publication has 26 references indexed in Scilit:
- Full Validation of an Analytical Method for the HIV-Protease Inhibitor Atazanavir in Combination With 8 Other Antiretroviral Agents and its Applicability to Therapeutic Drug MonitoringTherapeutic Drug Monitoring, 2006
- Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5Clinical Pharmacology & Therapeutics, 2005
- Antiretroviral Drug Pharmacokinetics in Hepatitis with Hepatic DysfunctionClinical Infectious Diseases, 2005
- Effects of grapefruit juice and orange juice components on P‐glycoprotein‐ and MRP2‐mediated drug effluxBritish Journal of Pharmacology, 2004
- Modifications and substitutions of the RNA extraction module in the ViroSeq™ HIV‐1 genotyping system version 2: Effects on sensitivity and complexity of the assayJournal of Medical Virology, 2003
- Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 TrialThe Journal of Infectious Diseases, 2003
- Population-based investigations of drug relative clearance using nonlinear mixed-effect modelling from information generated during the routine clinical careof patientsJournal of Clinical Pharmacy & Therapeutics, 1999
- Ritonavir and saquinavir combination therapy for the treatment of HIV infectionAIDS, 1999
- Safety and activity of saquinavir in HIV infectionThe Lancet, 1995
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973